These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 30920627)

  • 1. Association of Serum Paraoxonase/Arylesterase Activity With All-Cause Mortality in Maintenance Hemodialysis Patients.
    Suematsu Y; Goto M; Park C; Nunes ACF; Jing W; Streja E; Rhee CM; Cruz S; Kashyap ML; Vaziri ND; Narayanaswami V; Kalantar-Zadeh K; Moradi H
    J Clin Endocrinol Metab; 2019 Oct; 104(10):4848-4856. PubMed ID: 30920627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum paraoxonase activity in uremic predialysis and hemodialysis patients.
    Dirican M; Akca R; Sarandol E; Dilek K
    J Nephrol; 2004; 17(6):813-8. PubMed ID: 15593056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Relation between paraoxonase activity, other HDL components and inflammatory state in hemodialyzed patients].
    González AI; Brites F; Elbert A; Gómez-Rosso L; Berg G; Wikinski R; Schreier L
    Medicina (B Aires); 2010; 70(6):508-12. PubMed ID: 21163737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paraoxonase enzyme activity is enhanced by zinc supplementation in hemodialysis patients.
    Rahimi-Ardabili B; Argani H; Ghorbanihaghjo A; Rashtchizadeh N; Naghavi-Behzad M; Ghorashi S; Nezami N
    Ren Fail; 2012; 34(9):1123-8. PubMed ID: 22950600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acrolein inactivates paraoxonase 1: changes in free acrolein levels after hemodialysis correlate with increases in paraoxonase 1 activity in chronic renal failure patients.
    Gugliucci A; Lunceford N; Kinugasa E; Ogata H; Schulze J; Kimura S
    Clin Chim Acta; 2007 Sep; 384(1-2):105-12. PubMed ID: 17632094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes of serum paraoxonase (an HDL-cholesterol-associated lipophilic antioxidant) and arylesterase activities in severe preeclamptic women.
    Kumru S; Aydin S; Gursu MF; Ozcan Z
    Eur J Obstet Gynecol Reprod Biol; 2004 Jun; 114(2):177-81. PubMed ID: 15140512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum paraoxonase/arylesterase activities in phenylketonuric patients on diet.
    Schulpis KH; Bartzeliotou A; Tsakiris S; Gounaris A; Papassotiriou I
    Eur J Clin Nutr; 2007 Jun; 61(6):803-8. PubMed ID: 17203019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coronary artery disease is associated with the ratio of apolipoprotein A-I/B and serum concentration of apolipoprotein B, but not with paraoxonase enzyme activity in Iranian subjects.
    Rahmani M; Raiszadeh F; Allahverdian S; Kiaii S; Navab M; Azizi F
    Atherosclerosis; 2002 Jun; 162(2):381-9. PubMed ID: 11996958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum paraoxonase-1 activity is associated with light to moderate alcohol consumption: the PREVEND cohort study.
    Gruppen EG; Bakker SJL; James RW; Dullaart RPF
    Am J Clin Nutr; 2018 Dec; 108(6):1283-1290. PubMed ID: 30376039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased oxidized-LDL levels and arylesterase activity/HDL ratio in ESRD patients treated with hemodialysis.
    Mahrooz A; Zargari M; Sedighi O; Shaygani H; Gohari G
    Clin Invest Med; 2012 Jun; 35(3):E144-51. PubMed ID: 22673317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paraoxonase-1 concentrations in end-stage renal disease patients increase after hemodialysis: correlation with low molecular AGE adduct clearance.
    Gugliucci A; Mehlhaff K; Kinugasa E; Ogata H; Hermo R; Schulze J; Kimura S
    Clin Chim Acta; 2007 Feb; 377(1-2):213-20. PubMed ID: 17118352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of nandrolone decanonate on paraoxonase activity in hemodialysis patients.
    Ghorbanihaghjo A; Argani H; Rahbaninoubar M; Rashtchizadeh N
    Clin Biochem; 2005 Dec; 38(12):1076-80. PubMed ID: 16153628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The inverse association of HDL-cholesterol with future risk of hypertension is not modified by its antioxidant constituent, paraoxonase-1: The PREVEND prospective cohort study.
    Kunutsor SK; Kieneker LM; Bakker SJL; James RW; Dullaart RPF
    Atherosclerosis; 2017 Aug; 263():219-226. PubMed ID: 28667918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paraoxonase (PON)-1 activity in septic neonates: One more arrow in the quiver of biomarkers of neonatal sepsis?
    Bourika V; Bartzeliotou A; Spiliopoulou C; Michos A; Papassotiriou I; Siahanidou T
    Clin Biochem; 2021 Jul; 93():119-121. PubMed ID: 33831384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low high-density lipoprotein cholesterol is not responsible for decreased paraoxonase activity in chronic renal failure.
    Varga É; Seres I; Harangi M; Kárpáti I; Koncsos P; Sztanek F; Paragh G
    Kidney Blood Press Res; 2012; 35(4):265-72. PubMed ID: 22378349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incident type 2 diabetes is associated with HDL, but not with its anti-oxidant constituent - paraoxonase-1: The prospective cohort PREVEND study.
    Kunutsor SK; Kieneker LM; Bakker SJL; James RW; Dullaart RPF
    Metabolism; 2017 Aug; 73():43-51. PubMed ID: 28732570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Serum Triglyceride to HDL Cholesterol Ratio with All-Cause and Cardiovascular Mortality in Incident Hemodialysis Patients.
    Chang TI; Streja E; Soohoo M; Kim TW; Rhee CM; Kovesdy CP; Kashyap ML; Vaziri ND; Kalantar-Zadeh K; Moradi H
    Clin J Am Soc Nephrol; 2017 Apr; 12(4):591-602. PubMed ID: 28193609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased arylesterase activity of paraoxonase-1 (PON-1) might be a common denominator of neuroinflammatory and neurodegenerative diseases.
    Castellazzi M; Trentini A; Romani A; Valacchi G; Bellini T; Bonaccorsi G; Fainardi E; Cavicchio C; Passaro A; Zuliani G; Cervellati C
    Int J Biochem Cell Biol; 2016 Dec; 81(Pt B):356-363. PubMed ID: 27312742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of micronised fenofibrate on paraoxonase activity in patients with coronary heart disease.
    Paragh G; Seres I; Harangi M; Balogh Z; Illyés L; Boda J; Szilvássy Z; Kovács P
    Diabetes Metab; 2003 Dec; 29(6):613-8. PubMed ID: 14707891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinetics of HDL cholesterol and paraoxonase activity in moderate alcohol consumers.
    Sierksma A; van der Gaag MS; van Tol A; James RW; Hendriks HF
    Alcohol Clin Exp Res; 2002 Sep; 26(9):1430-5. PubMed ID: 12351939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.